Beijing Inno Medicine Co., Ltd. is a clinical-stage biotechnology leader specializing in the development of next-generation active targeted nano-therapies. Founded in 2016 by Dr. Qian Ma, the company has pioneered a first-in-class targeted delivery platform with global proprietary rights. By overcoming traditional biological barriers, Inno Medicine is transforming the treatment landscape for high-burden diseases, including Atherosclerosis and Glioma, where urgent unmet needs remain. Following the successful completion of our Phase 1b/2a trials with positive safety and efficacy data, we are now actively initiating a Phase 2b/3 pivotal study to accelerate the path to market.